SCHEMBL2749686

SCHEMBL2749686

Nc1ncc(-c2cnn(CC(=O)NCCO)c2)cc1-c1nc2ccccc2s1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.47
MGLL Q99685 1/20 0.42
MAPK1 P28482 5/20 0.41
IRAK4 Q9NWZ3 1/20 0.39
IKBKE Q14164 2/20 0.38
TBK1 Q9UHD2 2/20 0.38
KDR P35968 2/20 0.38
FGFR1 P11362 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
ILK Q13418 1/20 0.38
FYN P06241 1/20 0.37
BTK Q06187 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2750045 0.92 MET (0.49) METMGLLMAPK1IRAK4IKBKE
SCHEMBL2748900 0.90 MAPK1 (0.45) METMGLLMAPK1IKBKETBK1
SCHEMBL2750077 0.88 BTK (0.46) METMGLLMAPK1IKBKETBK1
SCHEMBL2749424 0.87 MET (0.49) METMGLLMAPK1IKBKETBK1
SCHEMBL2751069 0.86 MET (0.44) METMGLLMAPK1IRAK4IKBKE
SCHEMBL2751939 0.85 MET (0.50) METFGFR1FGFR2FGFR3BTK
SCHEMBL2751598 0.85 MAPK1 (0.43) METMAPK1IRAK4ILKFYN
SCHEMBL2749226 0.84 CCNC (0.47) METMGLLMAPK1
SCHEMBL2749325 0.83 MAPK1 (0.47) METMAPK1IKBKETBK1MEN1
SCHEMBL2749337 0.82 BTK (0.47) METMAPK1IKBKETBK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MET 38/4885MGLL 4848/4885MAPK1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.